Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.

about

Integrated approach to pain management for a patient with multiple bone metastases of uterine cervical cancer.

P2860

Q52349317-CBCCBB81-DFF3-4B12-A379-D15C789120FA

P2860

Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.

Item

http://www.wikidata.org/entity/Q38992409

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Long-term safety of monthly zo ...... tre prospective phase 4 study.

@en

type

Item

label

Long-term safety of monthly zo ...... tre prospective phase 4 study.

@en

prefLabel

Long-term safety of monthly zo ...... tre prospective phase 4 study.

@en

P1476

Long-term safety of monthly zo ...... tre prospective phase 4 study.

@en

P2093

B Chern

http://www.w3.org/2001/XMLSchema#string

E Abdi

http://www.w3.org/2001/XMLSchema#string

M C Copeman

http://www.w3.org/2001/XMLSchema#string

M Slancar

http://www.w3.org/2001/XMLSchema#string

R J Woodfield

http://www.w3.org/2001/XMLSchema#string

W Cosolo

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Recommendations for zoledronic acid treatment of patients with bone metastases.

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

P304

e12638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ECC.12638

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alhossain A Khalafallah

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28134499

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5901400

http://www.w3.org/2001/XMLSchema#string

Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.

about

P2860

P2860

Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932